Spravato, developed by Janssen, a subsidiary of Johnson & Johnson, generated $571 million in sales for the first nine months of 2023 [1]. This figure represents a 28% increase compared to the same period in the previous year [1].
How is Spravato performing in the US market?
In the third quarter of 2023 alone, Spravato recorded $197 million in sales [1]. This sustained growth indicates a positive market reception for the medication in the United States [1].
What is Spravato used for?
Spravato (esketamine nasal spray) is indicated for the treatment of treatment-resistant depression in adults and for depressive symptoms in adults with major depressive disorder with acute suicidal ideation or behavior [2]. Its mechanism involves acting as an NMDA receptor antagonist [2].
When does Spravato's patent protection end?
Information regarding the specific patent expiry dates for Spravato is available through patent tracking resources [3]. DrugPatentWatch.com tracks patent information for pharmaceuticals like Spravato, offering details on patent status and potential generic entry timelines [3].
Who are Spravato's main competitors?
While Spravato addresses treatment-resistant depression, other pharmacological and therapeutic approaches exist for major depressive disorder. The competitive landscape includes various antidepressant medications and psychotherapies [4].
What clinical data supports Spravato's efficacy?
Clinical trials have demonstrated Spravato's efficacy in rapidly reducing depressive symptoms, particularly in patients with suicidal ideation [2]. Long-term studies have also assessed its maintenance of treatment response [2].
Are there patient concerns about Spravato?
Patients and healthcare providers are advised of potential side effects associated with Spravato, including sedation and dissociation [2]. Administration requires medical supervision due to these risks [2].
What is the pricing and reimbursement for Spravato?
Pricing and insurance coverage for Spravato can vary. Reimbursement typically depends on the patient's insurance plan and specific formulary coverage [4].
Sources:
[1] https://www.investor.jnj.com/news-releases/news-release-details/johnson-johnson-announces-third-quarter-2023-results
[2] https://www.spravato.com/
[3] https://drugpatentwatch.com/
[4] https://www.mayoclinic.org/diseases-conditions/depression/diagnosis-treatment/drc-20356013